Lantheus Holdings Inc (LNTH)
Lantheus Holdings, Inc. is a healthcare company listed on NASDAQ under the ticker LNTH. It develops, manufactures, and commercializes diagnostic and therapeutic products used by clinicians in the diagnosis and treatment of heart disease, cancer, and other conditions across global markets. Its portfolio includes imaging and radiopharmaceutical products such as DEFINITY, TechneLite, Xenon-133, Neurolite, Cardiolite, and PYLARIFY, along with software and analytical tools including Automated Bone Scan Index, aPROMISE, and PYLARIFY AI. The company also markets RELISTOR and is advancing a pipeline that includes therapies and imaging agents such as PNT2002, PNT2003, MK-6240, and several LNTH-branded radiodiagnostic programs. Lantheus has collaboration agreements with GE Healthcare, Curium Pharma, POINT, Regeneron, and Ratio Therapeutics LLC. Founded in 1956 and based in Bedford, Massachusetts, the company operates as an ordinary common stock issuer in the healthcare equipment and supplies sector.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LNTH
|
$99.51
|
-5.9% Downside
|
Fair
|
$112
|
5.9% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
24.7x
|
5.7x
|
4.5x
|
6.797 B
|
7.025 B
|
8.4%
|
89.6%
|
6.7
|
—
|
135.1%
|
